On December 17, 2025, Knowledge Ecology International (KEI) provided comments to the National Institutes for Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer” (89 FR 95224) to… Continue Reading
On December 5, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola… Continue Reading
On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading
The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading
The National Institutes of Health (NIH) Office of Science Policy (OSP) posted a Request for Information (RFI) on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning. The draft policy seeks, “to promote access to products stemming… Continue Reading
Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading
On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading
On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading
Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading